Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,193.00
Bid: 2,193.00
Ask: 2,196.00
Change: -44.00 (-1.97%)
Spread: 3.00 (0.14%)
Open: 2,222.00
High: 2,237.00
Low: 2,191.00
Yest. Close: 2,237.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Hikma pulls gout tablets from US market

Jordan-based pharmaceuticals firm Hikma has sorted out its dispute with Mutual Pharmaceutical relating to the sale of oral colchicine tablets. Hikma's subsidiary and US agent, West-Ward Pharmaceutical, has discontinued its sales of oral colchicine until approval of its New Drug Application by the U

18 Oct 10 07:26

London close: Strong start to final quarter

The last quarter of 2010 started well for London's leading share index, with buoyancy in the oil sector helping to offset continuing economic worries at home and abroad. Manufacturing data was subdued. Footsie gave up some of its early gains after figures from the US showed Manufacturing grew at th

1 Oct 10 16:41

London afternoon: Footsie back above 5600

The afternoon session has seen the Footsie advance confidently, almost regaining its high for the day which was hit shortly after 10:00am. A solid start by Wall Street on the back of better than expected spending data has helped sentiment this side of the pond. Oil giant BP is higher amid speculat

1 Oct 10 14:56

Broker tips: Hikma, Aveva, Helphire

Some investors may be bailing on pharmaceuticals firm Hikma in the wake of the press speculation about a plan by US regulators to ban unapproved oral colchicine products to treat gout, but Panmure Gordon is sticking by the stock. "We note the company's announcement this morning regarding the seemin

1 Oct 10 13:24

Broker snap: Hikma slide is buying opportunity

Some investors may be bailing on pharmaceuticals firm Hikma in the wake of the press speculation about a plan by US regulators to ban unapproved oral colchicine products to treat gout, but Panmure Gordon is sticking by the stock. "We note the company's announcement this morning regarding the seemin

1 Oct 10 12:55

London midday: Stocks advance despite economic worries

London's leading share index remains in positive territory, but worries over the European debt situation have weighed on sentiment slightly. The concerns centre on Ireland again, after figures showed manufacturing activity in the country contracted in September, with the purchasing managers' index

1 Oct 10 12:23

London open: Oil stocks lift Footsie

Shares have got off to a strong start on the first day of the last quarter, with oil stocks setting the pace. BP is higher amid speculation that dividends will soon be resumed. Bob Dudley, who becomes chief executive of the oil company today, said that the board would meet soon to discuss restoring

1 Oct 10 09:13

London pre-open: BP divi hopes to lift Footsie

London looks set to start the final quarter of 2010 in positive mood with sentiment lifted by hints from the incoming boss of oil giant BP that the company is ready to restore dividend payments that were suspended during the Gulf of Mexico crisis. Bob Dudley, who becomes chief executive of the oil

1 Oct 10 07:37

Hikma shrugs off drug ban threat

Drugs group Hikma Pharmaceuticals has moved to calm fears about the impact of a plan by US regulators to ban unapproved oral colchicine products to treat gout. Its shares tumbled yesterday on the news. Investors also worried about comments from Numis analyst Jonathan Kwok that August's impressive i

1 Oct 10 07:10

MARKET TALK: JPMorgan Starts Hikma At Overweight

0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing leading long-term growth and the potential for a near-term EPS beat. Notes Hikma's competitive advantages as the top local player in the Middle East & North Africa pharmaceutical ma

6 Jul 10 08:17

UK MARKET TALK ROUNDUP: SHARES GAINING

Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing lea

6 Jul 10 08:17

MARKET TALK: Royal Bank of Scotland Starts Hikma Pharma At Hold

0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p target price. "Our optimistic forecasts reflect Hikma's strong position in MENA [Middle East and North Africa] and its strategy of globalizing the platform, which should allo

6 Jul 10 07:53

UK MARKET TALK ROUNDUP: BROKERS COMMENTS

Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p

6 Jul 10 07:53

MARKET TALK: UBS Raises Hikma Price Target

0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rates and a slightly higher interest charge than previously anticipated. Notes Hikma has launched oncology injectable products in the Middle East and North Africa, and says this is

23 Jun 10 09:16

UK MARKET TALK ROUNDUP: SHARES GAINING

Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, markets.eu@dowjones.com Contact us in London. +44-20-7842-9464 Markettalk.eu@dowjones.com 0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rat

23 Jun 10 09:16

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.